Biocon, Viatris application for Insulin Aspart rejected by USFDA
New Delhi: Biocon Biologics, a subsidiary of biotechnology major Biocon, on Friday said the US health regulator has not approved an application for Insulin Aspart filed by its partner Viatris Inc.
"The USFDA has issued a complete response letter (CRL) for the biologics licence application (BLA) for Insulin Aspart filed by our partner Viatris (Mylan)," a Biocon Biologics spokesperson said in a regulatory filing.
The company will respond to the CRL to satisfy the FDA's requests, it added.
The CRL did not identify any outstanding scientific issues with the product," the spokesperson noted.
"As per the USFDA, a CRL is sent to an applicant if the agency determines that it will not approve the application or abbreviated application in its present form," reports PTI.
Read also: Biocon Biologics partner Viatris wins US court decision on 5 Sanofi Lantus SoloSTAR device patents
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.